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ABST RACT
Rosacea is a chronic inflammatory skin disease with a complex
pathogenesis that mainly affects the central part of the face, with a global
incidence of 5.46%. The present study was performed on a group of 68
patients with rosacea 1 and 2 subtypes, patients between 34-63 years old.
The treatments were performed using a Cutera Xeo laser, using 2 types of
probes: NdYag 1064nm for telangiectasias and LimeLight 520-1100nm for
diffuse facial erythema, papules, and pustules, having an 10x30mm
window. For patients with diffuse facial erythema, etc., the optimal number
of sessions was between 3 and 6 with or without anesthetic cream, using
energies between 14-19J / cm. The average recovery time was 5 days.
Registered effects included bruises, pustules, burning sensation, transient
stinging, and hypopigmentation. For patients with telangiectasia, the
optimal number of sessions was two, performed at an average interval of
once per month/ monthly.

Introduction
Rosacea is a chronic inflammatory disease of the skin
with a complex pathogenesis that mainly affects the central
part of the face [1]. The term “rosacea” was introduced in
the 19th century by Thomas Bateman [2]. The disease
affects both sexes and can be found at any age, but
frequently, the debut of the disease occurs after the age of
30 years.
In women, there was an increased incidence of
erythematotelangiectatic and papulopustular rosacea, in
which the debut was recorded after the age of 40 [3]. The
incidence of the disease according to the latest reported
statistical data is between 0.09 and 22.41%, with an
average of 5.46% amongst world populations [4;5],
reaching up to 10% among the Caucasian population [6].
The disease is also more common for Fitzpatrick III and IV
phototypes, and lower for V and VI phototypes [6]. From
a clinical point of view, the disease is manifested by facial
erythema (transient or persistent), telangiectasia, edema,
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papules and pustules, burning sensation, stinging, pain or
itching; patients may show one or more signs and
symptoms [7]. There are also cases in which patients are
completely asymptomatic, the disease having only facial
skin signs [8]. The disease has a sinusoidal evolution, with
periods of remission and exacerbation. It is important to
emphasize the role of Demodex Folliculorum in the
appearance of Rosacea, because its number is increased in
confirmed patients compared to patients without rosacea,
questioning whether its multiplication directly or indirectly
produces rosacea, or alternatively whether rosacea is
favorable ground for its multiplication. Studies show that
Demodex Folliculorum can be present and multiplied
without producing rosacea, only spinulosis, including areas
other than the central facial area. Sometimes its presence
and associated endosymbiont bacteria, described in the
literature, can produce rosacea or demodeciosis with
inflammatory elements, objectified through spectrometric
bacteriological methods, imagistic- ex: VISIA dermoscopy
[9-12].
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Rosacea was classified into 4 main subtypes:
erythemothelothelectectic (subtype 1), papulopustular
(subtype 2), phytomatous (subtype 3), and ocular (subtype
4), granulomatous rosacea being considered a variant/type
of rosacea rather than a subtype. Since 2017, the
classification of rosacea is based on phenotypes and for the
diagnosis of rosacea, at least one diagnosis or two major
phenotypes are required [6].
The diagnostic phenotypes for rosacea are:
• Persistent erythema of the central face area that
worsens with some triggers
• Phytomatic changes (most commonly rhinophyma)
The major phenotypes for rosacea are:
• Transient facial erythema of the central face
• Inflammatory papules and pustules
• Telangiectasias
• Ocular changes: blepharitis, keratitis, conjunctivitis,
ocular telangiectasias
Minor phenotypes for rosacea are:
•
•
•
•

Burning sensation
Stings
Edema
Dryness [13].

Also, a particular type of rosacea is the secondary one,
induced by the prolonged use of cutaneous
dermatocorticoids or calcineurin inhibitors [14-17].

Materials and Methods
The present study is based on 68 patients, with the age
between 34-63 years with a prevalence of women (76%).
The inclusion criteria were: patients with rosacea subtypes
1 and 2. Exclusion criteria were: patients with rosacea
subtypes 3 and 4.
The treatments were performed with the Cutera Xeo
laser, using 2 probes: NdYag 1064 nm and LimeLight 5201100 nm, with a 10x30 mm window. The protocol used in
the study was:
− for telangiectasia (cuperosic stage of the disease),
NdYag treatment was applied, 1 session every 1-2
months. The working parameters were: 3 mm spot,
time 15-25 ms, energy 110-130 J / cm2.
− for diffuse facial erythema, papules, and pustules, the
LimeLight probe was applied, 1 session of 3-4 weeks,
program A (vascular) and an energy of 15-19 J / cm2.
Since the two conditions usually exist simultaneously,
the following steps have been followed: LimeLight
sessions were done every 3-4 weeks, followed by the 2
NdYag sessions.
The treatments were performed exclusively between
October and May of the same year. For maintenance, we

recommend 1-2 sessions of LimeLight annually during
winter.
Post-procedure,
all
patients
received
recommendations to use a mixture of cream with a
protection factor of at least 50% during the entire length of
treatment, to avoid exposure to excessive heat such as
sauna, sun, or solarium exposure, and to avoid alcohol
consumption.

Results
For patients with diffuse facial erythema, papules, etc.,
the optimal number of sessions with the LimeLight probe
was 4, at intervals of 3-4 weeks. The maximum number of
sessions was 6, the fewest 3. Most treatments were
performed without anesthetic cream though some patients
wanted to use the cream. The degree of discomfort during
the procedure was medium, and the treatments were started
from energies of 14-15 J/cm2 and increased progressively,
from session to session, to energies of 18-19 J/cm2. The
average recovery time was 5 days, during which the patient
presented with severe edema. As side effects, there were
small bruises, small pustules, burning sensation, and
transient stinging. As complications, in 3 patients there
were observed areas of hyperpigmentation, partially
remitted. We did not record any post-procedure scars.
Although after the first sequence of LimeLight procedure,
many patients said they would stop treatment, ultimately
all patients completed the treatment.
For patients with telangiectasia, the optimal number of
sessions was 2, performed on average monthly.
Telangiectasia disappeared completely after these 2
sessions. As for complications, in two cases there were
small excavations in the nose, instead of blood vessels,
almost imperceptible but permanent. As an advantage,
however, a reduction in the volume of the nose was
observed. The area of predilection treated was that of the
nose, followed by the chin and only in a few cases by the
zygomatic areas. It did not require recovery time and the
treatment was well tolerated by all patients. No local
anesthesia was required.

Discussions
It is known that rosacea has negative effects on quality
of life, including psychosocial well-being in people with
mild, moderate, or severe erythema. However, this impact
on self-perception and emotional, social, and general wellbeing is significantly higher in people with severe
erythema [18]. Thus, we paid special attention to
improving the quality of life of these patients [19]. In this
case, the end results were very positive, with an excellent
aesthetic result and with complete remission of the
symptoms in most cases. The degree of satisfaction of the
patients was very good, with the return to normal of their
self-confidence and well-being.
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Rosacea treatment is not standardized; we are still
seeking optimal treatment protocols. One of the usual
therapeutic approaches for rosacea is based on reducing
inflammation, using various drugs and substances such as
doxycycline [20], metronidazole [21], topical azelaic acid
[22], sodium sulfacetamide [23] and calcineurin inhibitors,
[24], ivermectin, pimecrolimus, retinoids, permethrin,
benzoyl peroxide, erythromycin, and dapsone [25].
Utilization of serine protease inhibitors is considered an
emerging therapy for rosacea [26]. Isotretinoin has also
been used in patients with papulopustular subtype rosacea
[27]. But this approach is useful only in the early stages,
with the improvement of symptoms, though with
suboptimal aesthetic results and in most cases with a nonnegligible toxicity for the body, with gastrointestinal
disorders or increased photosensitivity.
Recently, photodynamic therapy (PDT) has
increasingly gained ground [28,29], sometimes in
association with other treatments such as methyl ester
aminolevulinate (MAL) [30]. Furthermore, an in vitro
study performed on mouse skin showed that the most
effective wavelengths are 630 nm and 940 nm, which
decrease some mediators of rosacea inflammation, such as
cathelicidin (LL-37), TLR2 and kallikreins (KLKs) [31].
Photodynamic therapy also interacts with the skin
microbiome [32]. Research is currently continuing on the
effectiveness of blue and red light on the skin’s microflora
in patients with rosacea and acne patients [33].
Different types of lasers with wavelengths between
400-1400 nm are used to treat diffuse facial erythema.
Thus, in addition to intensely pulsed light that involves a
wide spectrum of wavelengths, 595 nm colored pulse lasers
(PDL) are also used. Furthermore, the use of intensely
pulsed light at a wavelength of 560 nm is as effective as the
PDL laser in the treatment of facial erythema, but with
much lower side effects than the PDL laser and with a
shorter recovery time [32], this being the main
consideration for using a laser with intense pulsed light and
not a PDL. Most people who present with rosacea are
active people who cannot afford long periods of recovery.
[34].
For the treatment of telangiectasias, the range of lasers
used is larger. However, the principle underlying their
functioning in the case of vascular lesions is the same,
namely the absorption of energy by hemoglobin [35]. Thus,
the lasers used to treat telangiectasia are: 1064 nm
Neodymium-doped, yttrium – aluminum – garnet (NdYAG), 532 nm Potassium-Titanium-Phosphate (KTP), 595
nm PDL, dual wavelength long-pulsed 775 nm alexandrite/
1,064 nm neodymium: yttrium-aluminum (LPAN) [36].
The most used lasers, however, remain by far NdYag 1064
nm and PDL 595 nm.
As far as the approach order of rosacea lesions, all
authors prefer to use in the first stage intense pulsed light
208

(IPL) followed by the use of NdYag or PDL lasers to close
telangiectasia [25], an approach that we have used in our
clinic. NdYag lasers have the advantages over PDL of less
pain production, shorter recovery time, and fewer
complications, yet with results that are comparatively the
same [25], and thus, the basis for choosing the NdYag laser
and not a PDL in the treatment of telangiectasia. The
efficiency of NdYaG lasers can be increased by combining
it with topical substances based on retinoic acid (some
authors find this increases potency up to 47%) or vitamin
C or D [37-39]. In recent years, radiofrequency devices
have been used to treat telangiectasia, but thus far, results
are not promising, with radiofrequency tending to be
overrated as a good-for-everything technique [40].
Recently, Botox has been introduced as a therapeutic
method in the treatment of rosacea: it seems its actions take
place through the nervous system by lowering local
vascularity, but the mode of action and efficacy are yet to
be fully evaluated [41].
The factors that lead to the appearance of rosacea are
not fully elucidated. Some innate or acquired immune
dysfunctions are often associated with several
neurovascular dysfunctions, with a genetic component
underlying the appearance of rosacea [42]. These
dysfunctions are directly or indirectly associated Demodex
Folliculorum (DF) (through its own bacteria
endosymbiosis, or other bacteria unrelated to DF such as
Staphylococcus), epidermidis, ultraviolet (UV) radiation,
extreme temperatures, stress, congestive foods, and the
presence of metabolic syndrome or diabetes mellitus [3841]. DF has been shown to have Bacillus bacteria
endosymbionts such as Bacillus Oleronius, Bacillus
Pumilus, Bacilus simplex, Cereus or Corynebacterium
kroppenstedtii [44-46].
DF, either directly or through its endosymbionts, can
trigger the cascade of immunologically active peptides by
interacting directly or indirectly with various structures,
including receiver type. It has also been found that some
skin receptors exhibit enhanced receptivity, such as Tolllike receptor (TLR) 2, nucleotide-binding oligomerization
domain (NOD)-like receptor, and transient vanilloid
receptor potential (TRPV4). Activation of these receptors
causes the production of immune peptides (eg, LL-37) and
various cytokines and chemokines, which induce a variety
of inflammatory reactions [47]. The TLR2 receptor can
also activate kappa B nuclear transcription factor (NF-kB),
further accentuating inflammation [48]. Implicitly, they
will also cause neurovascular changes. Mast cells also
participate in the appearance of rosacea by increasing
inflammation, angiogenesis, and fibrosis [49]. More
recently, rosacea and other skin diseases such as psoriasis
and atopic dermatitis have been linked to intestinal
dysbiosis, although the role of the association of
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Helicobacter pylori infection or SIBO-small intestinal
bacterial overgrowth is still debated [50]. However, the
cascade of inflammatory reactions and triggers is much
wider. Thus, keratinocytes will release cathelicidin,
vascular endothelial growth factor and endothelin-1,
endothelial cells will release nitric oxide, mast cells will
release cathelicidin and matrix metalloproteinases,
macrophages will release interferon-gamma, tumor
necrosis factor, matrix metalloproteinase and interleukin26 and in addition, all these factors can communicate
directly with the cutaneous nervous system through active
neurovascular neuropeptides. The consequences of these
many pathophysiological changes over the long term are:
vasodilation, glandular hyperplasia, and fibrosis. The
presence of rosacea may contraindicate or limit the
indications for some dermato-cosmetic treatments such as
chemical peels or hyaluronic acid treatments [51-53]. It
may also limit the use of other types of lasers for various
dermatological conditions that induce local vasodilation; in
these cases, the order of treatment must be analyzed [5455].

Conclusions
Rosacea is a dermatological condition with
multifactorial etiology. Its clinical forms require complex
treatments on the one hand, combined, both topical and
systemic but also by using NdYag laser devices and intense
pulsed light; on the other hand, the treatments are adapted
to the particularities and comorbidities associated with
rosacea in our patients.
This paper presents the results of the treatments
performed, with the help of a Cutera Xeo laser, using 2
probes: NdYag 1064 nm and LimeLight 520-1100 nm,
with a window of 10x30 mm. The maximum number of
sessions was 6, the minimum was 3. Most treatments were
made without anesthetic cream though some patients
wanted anesthetic cream. The degree of discomfort during
the procedure was medium, and treatments were started
from energies of 14-15 J / cm2 and increased progressively,
from session to session, to energies of 18-19 J / cm2. The
average recovery time was 5 days, during which the patient
presented severe edema. As side effects, there were small
bruises, small pustules, burning sensation, and transient
stinging. As complications there were registered, in 3
patients, areas of hyperpigmentation which partially
remitted. We did not observe post-procedure scars.
Rosacea treatment remains to be individualized according
to the needs and status of patients.
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